Secondary outcomes for the effect of randomized treatment arm in longitudinal analysis for first 6 months

Outcome	33% tapering				66% tapering			
	Unadjusted coefficient (95% CI)	P-value	Adjusted coefficient[a] (95% CI)	P-value	Unadjusted coefficient (95% CI)	P-value	Adjusted coefficient[a] (95% CI)	P-value
DAS28-ESR	0.13 (−0.20, 0.47)	0.438	0.06 (−0.25, 0.38)	0.690	0.44 (0.07, 0.80)	<0.02	0.36 (0.02, 0.70)	<0.05
DAS28-CRP	−0.05 (−0.27, 0.18)	0.671	−0.05 (−0.27, 0.18)	0.685	0.17 (−0.08, 0.41)	0.188	0.18 (−0.07, 0.42)	0.163
Tender joint counts	0.07 (−0.76, 0.91)	0.864	0.05 (−0.78, 0.88)	0.911	1.34 (0.42, 2.25)	<0.01	1.32 (0.42, 2.22)	<0.01
Swollen joint counts	−0.17 (−0.71, 0.37)	0.530	−0.21 (−0.74, 0.32)	0.438	0.97 (0.39, 1.56)	0.001	0.88 (0.30, 1.46)	<0.01
ESR	−0.97 (−5.06, 3.11)	0.641	−1.07 (−4.15, 2.00)	0.494	−3.47 (−7.89, 0.96)	0.124	−3.87 (−7.21, −0.53)	<0.05
CRP	−2.60 (−5.50, 0.30)	0.079	−2.86 (−5.67, −0.05)	0.050	−4.34 (−7.49, −1.18)	0.01	−4.28 (−7.34, −1.21)	<0.01
Assessor global	0.86 (−5.15, 6.86)	0.779	0.72 (−5.30, 6.73)	0.815	5.23 (−1.27, 11.73)	0.115	5.11 (−1.40, 11.63)	0.124
Patient global	2.64 (−3.32, 8.59)	0.385	3.00 (−2.73, 8.74)	0.305	4.82 (−1.62, 11.27)	0.142	5.34 (−0.87, 11.55)	0.092
HAQ	0.04 (−0.10, 0.17)	0.591	0.03 (−0.10, 0.15)	0.690	0.15 (0.01, 0.30)	<0.05	0.13 (−0.01, 0.27)	0.071
EQ5D-3L	−0.04 (−0.12, 0.03)	0.249	−0.03 (−0.10, 0.04)	0.402	−0.05 (−0.13, 0.03)	0.248	−0.04 (−0.11, 0.04)	0.326
VAS pain	6.62 (−1.83, 15.06)	0.125	5.10 (−2.49, 12.69)	0.188	3.85 (−5.30, 12.99)	0.410	0.79 (−7.55, 9.13)	0.853
FACIT fatigue	−0.35 (−2.93, 2.24)	0.793	−0.58 (−3.01, 1.85)	0.642	1.41 (−1.38, 4.20)	0.321	1.03 (−1.60, 3.65)	0.444
Larsen scores	−0.21 (−1.69, 1.27)	0.780	0.13 (−1.39, 1.64)	0.665	0.35 (−1.25, 1.96)	0.867	0.63 (−0.98, 2.25)	0.437

[a]The model was adjusted for age at registration, gender and disease duration. EQ5D-3L: EuroQol 5-dimension scale; FACIT: Functional Assessment of Chronic Illness Therapy; VAS: visual analogue scale.